New Article Collection on Antipsychotic Discontinuation! This new series of papers explores whether dose reduction or withdrawal is advisable and the risks associated with such a procedure. @sirsofficial.bsky.social Collection: go.nature.com/4pS4EA2

🏛 SIRS 2026 Elections – Nominations Open! We’re accepting nominations for: ✨ President-Elect ✨ Board Members (6 positions) ✨ Junior Board Members (3 positions) Help shape the Society’s future. 🗓 Deadline: 28 November 2025 🔗: sirs.societyconference.com?conf_id=1002... #SIRS2026

👉New Article Collection! We are proud to highlight our new article collection, Pathways to prevention: background and methodology for the Accelerating Medicines Partnership® Schizophrenia Program @sirsofficial.bsky.social go.nature.com/495Z3Av

Schizophrenia isn’t just in the brain. 🧠💔🦴 New study (Xie et al., 2025, Schizophrenia) maps shared genetic links between SCZ and heart, bone & abdominal organ imaging traits—revealing its truly systemic nature and new therapeutic targets. 🔗 www.nature.com/articles/s41...

New research explores how childhood trauma and violence intersect in schizophrenia. Reduced connectivity between the orbitofrontal & temporal brain regions mediates this link—potential neural targets for trauma-related interventions. 🔗 www.nature.com/articles/s41...

In Clinical High Risk research, how participants are recruited matters. Recruitment sources influence sex, age, and clinical profiles, shaping the heterogeneity seen across CHR studies. Accounting for these differences is crucial when interpreting findings. 🔗 Article: www.nature.com/articles/s41...

New review addressing the knowledge gap between voice hearing in psychosis and perceptual experiences in other sensory modalities with overview of voices and altered perceptual experiences across psychotic, mood and anxiety disorders @sirsofficial.bsky.social bit.ly/3J5ibDW

A New Chapter for Schizophrenia Journal... 📖

New investigation of what lies behind the 17-year reduction in life expectancy gap between #schizophrenia patients and the general population. 2nd-gen antipsychotics and low frequency hospitalization were associated with reduced mortality @sirsofficial.bsky.social bit.ly/4gdulqF

💡 New Findings in Clozapine Pharmacokinetics 🔗 Read the study here: doi.org/10.1038/s415... #Clozapine #Pharmacokinetics #Inflammation #Schizophrenia

📆 September is here! Your SIRS Submission Deadlines are Approaching FAST! Be Part of the Conversation in Florence, Italy Submit Your Symposia Proposal Today! #SIRS2026 LINK: sirs.societyconference.com/v2/#card/sub...

New study found longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance. @sirsofficial.bsky.social bit.ly/3JHvj26

How can smartphone and wearable digital biomarkers inform about risk of developing schizophrenia? Learn more about the use of digital phenotyping in the #AMP_SZ study in this new paper #biomarkers @SIRSGlobal bit.ly/4kxW1qH

Advances in proteomics & genomics are shedding light on biomarkers linked to schizophrenia risk. The AMP® Schizophrenia study is tracking 2,000+ participants to uncover blood & saliva markers that predict outcomes & reveal underlying biology. #Psychiatry #Biomarkers #AMP_SCZ bit.ly/3IB5Dn6

🚨 AMP SCZ EEG Study! 🧠⚡ CHR patients need better treatments. EEG biomarkers show strong reliability & potential for predicting outcomes, tracking illness, & guiding interventions #EEG bit.ly/46ungiw

Curious about predicting clinical outcomes? New paper in @schizjournal.bsky.social special issue shows how multidisciplinary experts shaped the AMP #Schizophrenia analysis strategy. Explore key decisions & data-driven insights! @sirsofficial.bsky.social @NoraPenzel @poloscience go.nature.com/4lYwQzv

Getting lived experience to guide psychosis research: The AMP® SCZ program integrates voices of those with lived experience into every stage to foster trust, enhance research outcomes, and inform future strategies for treatment and prevention @sirsofficial.bsky.social go.nature.com/4lIGYfu

Dr Jean Addington discusses the challenges and highlights the most important aspects of the selection and application of clinical assessment and outcome measures in the large multisite AMP®SCZ study investigating CHR go.nature.com/4cHoQ1r @sirsofficial.bsky.social vimeo.com/1040425281

New pathways for preventing schizophrenia: public and private partners collaborate in the international Accelerating Medicines Partnership® Schizophrenia consortium @sirsofficial.bsky.social go.nature.com/3Y89zks

Our new paper titled "The MR #neuroimaging protocol for the Accelerating Medicines Partnership® #Schizophrenia Program" is now published in @schizjournal.bsky.social www.nature.com/articles/s41...

Late highlight at #SIRS2025 @sirsofficial.bsky.social well worth staying for: symposium on cognitive impairments in psychosis, with chairs @rob-mccutcheon.bsky.social & Ingrid Melle (pic), and Sherry KW Chan, David Lewis, Richard Keefe - highlighting course, contributors, and ways forward.

New paper revealing the intricate data operations behind the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project, managing data across two research networks comprising 43 international sites bit.ly/43NfHlS @sirsofficial.bsky.social

Keynote on digital interventions for psychosis: Mario Alvarez-Jimenez kicking off day 3 @ #SIRS2025 @sirsofficial.bsky.social with powerful images on the omnipresence of technology in our daily lives - before elegantly demonstrating how this could be exploited to address current treatment challenges

Great symposium on self-disorders in schizophrenia at #SIRS2025 (@sirsofficial.bsky.social), spearheaded by @jfeyaerts.bsky.social, with exciting empirical findings presented by @ccrosenphd.bsky.social (20-year follow-up!) and Julia Lebovitz, and a stimulating discussion by Louis Sass.

Day two is here of #SIRS2025. We are still riding the wave from last night's keynote with Dr. Vikram Patel. Today, we continue to dive deeper into "Innovation Integration: Uniting Research and Practice in Schizophrenia." Let's make this another memorable day!

Don't miss today's Plenaries: ➡️ "Adolescent Stress as a Risk Factor for Schizophrenia: Insight from Animal Models" with Dr. Anthony Grace 🕘 9 AM - 10 AM ➡️ "Maintenance Treatment Strategies in Psychotic Disorders " with Dr. Christy Hui 🕘 2 PM - 3 PM 📍

Welcome to Chicago, SIRS 2025 attendees! Let's make this conference an experience to remember. We hope you enjoy our lineup of speakers and the chance to connect with colleagues in the field. #SIRS2025

Get the most out of your SIRS 2025 journey with conference app access, checking daily email updates, and skipping the wait by registering early!

Schizophrenia Journal is also LinkedIn www.linkedin.com/in/schizophrenia-journal-430825357/

New study in Schizophrenia Journal presenting a new mouse model for mental illness research, suggesting that stress-induced formaldehyde may function as an endogenous trigger for schizophrenia @nature.com bit.ly/4l3MWaN

Schizophrenia Journal @schizjournal.bsky.social is also on X x.com/schizjournal 🪶and LinkedIn www.linkedin.com/in/schizophr...

Cognition is a core biomarker for schizophrenia & key focus in the Accelerating Medicines Partnership® (AMP SCZ) initiative. Here the authors outline the rationale and harmonization of the cognitive battery @kelly_allott @Wal_yas @ @scottwoods01.bsky.social @patmcgorry.bsky.social bit.ly/4iWAFmA